Cargando…
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
BACKGROUND: Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. This study evaluated the efficacy and safety of sofosbuvir-based regimen in genotype 3 patients in a real-world setting. METHODS: HCV genotype 3a-infected adults with compensated liver disea...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547524/ https://www.ncbi.nlm.nih.gov/pubmed/31159813 http://dx.doi.org/10.1186/s12985-019-1184-y |
_version_ | 1783423696940040192 |
---|---|
author | Han, Qunying Fan, Xiude Wang, Xiaoyun Wang, Ye Deng, Huan Zhang, Xiaoge Zhang, Kun Li, Na Liu, Zhengwen |
author_facet | Han, Qunying Fan, Xiude Wang, Xiaoyun Wang, Ye Deng, Huan Zhang, Xiaoge Zhang, Kun Li, Na Liu, Zhengwen |
author_sort | Han, Qunying |
collection | PubMed |
description | BACKGROUND: Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. This study evaluated the efficacy and safety of sofosbuvir-based regimen in genotype 3 patients in a real-world setting. METHODS: HCV genotype 3a-infected adults with compensated liver disease were treated with sofosbuvir (SOF)/velpatasvir (VEL) or SOF/daclatasvir (DCV) with or without ribavirin (RBV) for 12 or 24 weeks, respectively. Efficacy was measured by sustained virologic response at post-treatment week 12 (SVR12). Adverse events were evaluated throughout the treatment and follow-up course. RESULTS: A total of 41 genotype 3a-infected patients were included. Of them, 10 patients (24%) had cirrhosis, 3 (7%) had renal impairment, and 2 (5%) failed previous treatment. Nine patients (22%) were treated with SOF/VEL and 32 (78%) with SOF/DCV with or without RBV. SVR 12 was achieved in 100% (9/9) of patients treated with SOF/VEL for 12 weeks and in 97% (31/32) of those treated with SOF/DCV for 12 or 24 weeks. RBV addition and extension of treatment duration did not improve the SVR of SOF/DCV (RR: 1.04; P = 0.99 and RR: 1.09; P = 0.375, respectively). Ten patients with cirrhosis, 1 on hemodialysis and 2 with treatment-experience achieved SVR12. One treatment-naïve non-cirrhotic patient on hemodialysis treated with SOF/DCV for 24 weeks relapsed at week 8 post-treatment. No serious adverse events and relevant laboratory abnormalities were observed. CONCLUSION: SOF/VEL and SOF/DCV are highly efficacious and well tolerated in genotype 3a-infected patients with or without cirrhosis. RBV coadministration and extension of SOF/DCV treatment appear to add no improvement for efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-019-1184-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6547524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65475242019-06-06 High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting Han, Qunying Fan, Xiude Wang, Xiaoyun Wang, Ye Deng, Huan Zhang, Xiaoge Zhang, Kun Li, Na Liu, Zhengwen Virol J Research BACKGROUND: Patients with hepatitis C virus (HCV) genotype 3 infection remain a difficult-to-cure population. This study evaluated the efficacy and safety of sofosbuvir-based regimen in genotype 3 patients in a real-world setting. METHODS: HCV genotype 3a-infected adults with compensated liver disease were treated with sofosbuvir (SOF)/velpatasvir (VEL) or SOF/daclatasvir (DCV) with or without ribavirin (RBV) for 12 or 24 weeks, respectively. Efficacy was measured by sustained virologic response at post-treatment week 12 (SVR12). Adverse events were evaluated throughout the treatment and follow-up course. RESULTS: A total of 41 genotype 3a-infected patients were included. Of them, 10 patients (24%) had cirrhosis, 3 (7%) had renal impairment, and 2 (5%) failed previous treatment. Nine patients (22%) were treated with SOF/VEL and 32 (78%) with SOF/DCV with or without RBV. SVR 12 was achieved in 100% (9/9) of patients treated with SOF/VEL for 12 weeks and in 97% (31/32) of those treated with SOF/DCV for 12 or 24 weeks. RBV addition and extension of treatment duration did not improve the SVR of SOF/DCV (RR: 1.04; P = 0.99 and RR: 1.09; P = 0.375, respectively). Ten patients with cirrhosis, 1 on hemodialysis and 2 with treatment-experience achieved SVR12. One treatment-naïve non-cirrhotic patient on hemodialysis treated with SOF/DCV for 24 weeks relapsed at week 8 post-treatment. No serious adverse events and relevant laboratory abnormalities were observed. CONCLUSION: SOF/VEL and SOF/DCV are highly efficacious and well tolerated in genotype 3a-infected patients with or without cirrhosis. RBV coadministration and extension of SOF/DCV treatment appear to add no improvement for efficacy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-019-1184-y) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-03 /pmc/articles/PMC6547524/ /pubmed/31159813 http://dx.doi.org/10.1186/s12985-019-1184-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Han, Qunying Fan, Xiude Wang, Xiaoyun Wang, Ye Deng, Huan Zhang, Xiaoge Zhang, Kun Li, Na Liu, Zhengwen High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting |
title | High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting |
title_full | High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting |
title_fullStr | High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting |
title_full_unstemmed | High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting |
title_short | High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting |
title_sort | high sustained virologic response rates of sofosbuvir-based regimens in chinese patients with hcv genotype 3a infection in a real-world setting |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547524/ https://www.ncbi.nlm.nih.gov/pubmed/31159813 http://dx.doi.org/10.1186/s12985-019-1184-y |
work_keys_str_mv | AT hanqunying highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT fanxiude highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT wangxiaoyun highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT wangye highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT denghuan highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT zhangxiaoge highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT zhangkun highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT lina highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting AT liuzhengwen highsustainedvirologicresponseratesofsofosbuvirbasedregimensinchinesepatientswithhcvgenotype3ainfectioninarealworldsetting |